Altered serum levels of glial cell line‐derived neurotrophic factor in male chronic schizophrenia patients with tardive dyskinesia

Ye, Fei; Zhan, Qiongqiong; Xiao, Wenhuan; Sha, Wei; Zhang, Xiaobin

doi:10.1002/mpr.1727

Cited by 6 publications

(4 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study found that serum GDNF levels in schizophrenia patients with a movement disorder called tardive dyskinesia (TD), which is thought to be due to long-term antipsychotic drug use, were lower than in normal controls and patients with schizophrenia without TD. This may indicate a neuroprotective effect of GDNF [ 18 ]. In sum, the relationship between GDNF levels and the pathogenesis of schizophrenia has not yet been sufficiently investigated, and therefore new studies are needed.…”

Section: Introductionmentioning

confidence: 99%

BDNF, GDNF, NGF and Klotho levels and neurocognitive functions in acute term of schizophrenia

et al. 2021

View full text Add to dashboard Cite

Background Klotho and its relationship with neurotrophic factors and cognition in schizophrenia has not yet been investigated. In this study, the hypothesis that the blood serum levels of BDNF, GDNF, NGF and Klotho in schizophrenia patients and healthy controls would be related to cognitive functions was investigated. Methods In this study, two groups were assessed: schizophrenia patients (case group) who were hospitalised in the Psychiatry Clinic of Sakarya University Training and Research Hospital and healthy volunteers (control group). The patients were evaluated on the 1st and 20th days of their hospitalisation with the Positive and Negative Syndrome Scale (PANSS), the Brief Psychiatric Rating Scale (BPRS), the General Assessment of Functioning Scale (GAF) and the Clinical Global Impression Scale (CGI). For cognitive assessment, both groups were evaluated with the Wechsler Memory Scale-Visual Production Subtest (Wechsler Memory Scale III-Visual Reproduction Subtest) and the Stroop test. Results BDNF, GDNF, NGF and Klotho levels were lower in schizophrenia patients than in healthy controls. In the schizophrenia patients, on the 20th day of treatment, there was a statistically significant increase in BDNF compared to the 1st day of treatment. BDNF, GDNF and Klotho showed positive correlations with some cognitive functions in the healthy controls. BDNF, GDNF, NGF and Klotho levels were intercorrelated and predictive of each other in both groups. Conclusion This study suggests a relationship between cognitive functions, neurotrophic factors and Klotho. Most of the results are the first of their kind in the extant literature, while other results are either similar to or divergent from those generated in previous studies. Therefore, new, enhanced studies are needed to clarify the role of Klotho and neurotrophic factors in schizophrenia.

show abstract

Section: Introductionmentioning

confidence: 99%

BDNF, GDNF, NGF and Klotho levels and neurocognitive functions in acute term of schizophrenia

et al. 2021

View full text Add to dashboard Cite

show abstract

“…A similar study by Xiao et al reported a GDNF serum level reduction in patients with cognitive impairment ( 25 ). GDNF serum level has enormously implicated in many other neurological disorders ( 26 – 28 ). These are consistent with our findings which revealed a reduced GDNF serum levels in patients with PD who are constipated.…”

Section: Discussionmentioning

confidence: 99%

Lower GDNF Serum Level Is a Possible Risk Factor for Constipation in Patients With Parkinson Disease: A Case–Control Study

Chen

Xue

et al. 2022

Front. Neurol.

View full text Add to dashboard Cite

Background: Constipation is a significant symptom of Parkinson's disease (PD). Glial-derived neurotrophic factor (GDNF) is important for the morphogenesis of the enteric nervous system and plays a critical role in the preservation of mucosal integrity under enteric glia surveillance. The aim of this work was to evaluate the serum levels of GDNF in patients with PD with and without constipation.Methods: This work included 128 patients with PD. The patients were classified into three groups: those with PD but no constipation (nCons-PD) (n = 49), those with prodromal stage constipation (Cons-Pro-PD) (n = 48), and those with clinical stage constipation (Cons-Clinic-PD) (n = 31). The association between serum GDNF concentration and constipation was explored using logical regression.Results: The nCons-PD group's mean GDNF levels were 528.44 pg/ml, which was higher than the Cons-Pro-PD group's 360.72 pg/ml and the Cons-Clinic-PD group's 331.36 pg/ml. The results of binary logistic regression indicated that GDNF was a protective factor in the prevention of constipation. Cons-Clinic-PD group had a higher score of MDS-UPDRS-II, MDS-UPDRS-III, MDS-UPDRS-IV, and a higher H-Y staging as compared with nCons-PD group. Relative to the nCons-PD group, Cons-Clinic-PD had higher NMSS scores, lower MoCA and PDSS scores, and were more likely to have RBD.Conclusions: GDNF serum levels are lower in patients with PD who are constipated. A low GDNF level is a potential risk factor for constipation in patients with PD.

show abstract

“…Although the data collected on the role of neurotrophines in the pathophysiology of bipolar disorder has increased, they are conflicting and far from being sufficient [12]. Moreoever, it is argued that these neurotropic factors also change in other psychiatric diseases such as major depression and schizophrenia, which implies that the change in these factors may not be unique to bipolar disorder [37,38]. In order to reveal this point, we kept cortisol level, BMI and age under control statistically in the groups and we found that GDNF and Nrn 1 levels were significantly lower while IGF-1 levels were significantly higher in bipolar manic episode patients compared to the control group.…”

Section: Discussionmentioning

confidence: 99%

Neurotrophic factors in bipolar disorders patients with manic episode

Tunçel¹,

Sarısoy²,

Çetin³

et al. 2020

Turk J Med Sci

View full text Add to dashboard Cite

Background/aim: Neurotrophins are one of the most important molecule groups affecting cerebral neuroplasticity. The amount of evidence about the role of changes in neuroplasticity in the pathophysiology of bipolar disease is growing. Materials and methods: We measured serum levels of brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophin-3 (NT-3), glial cell-line derived neurotrophic factor (GDNF), vascular endothelial growth factor (VEGF), insulin-like growth factor-1 (IGF-1), fibroblast growth factor (FGF)-2, neuritin 1 (Nrn 1) in bipolar 1 manic episode patients (n = 45) and healthy control group. Results: When controlled for age, BMI and cortisol, it was found that the serum levels of BDNF, NGF, NT-3, VEGF and FGF-2 of bipolar manic episode patients were not statistically different compared to those of the control group. GDNF level and Nrn 1 levels were significantly lower (P = 0.003 and P = 0.025 respectively) while IGF-1 levels were significantly higher than the control group (P = 0.0001). ROC analysis was performed and the area under the the curve was calculated as 0.737, 0.766 for GDNF, IGF-1 respectively. Conclusion: The changes in the levels of GDNF, IGF-1 and Nrn 1 might be involved in pathopysiology of bipolar disorder, and GDNF, IGF-1 may be considered as state markers in bipolar manic episode.

show abstract

Altered serum levels of glial cell line‐derived neurotrophic factor in male chronic schizophrenia patients with tardive dyskinesia

Abstract: Decreased GDNF levels in TD patients indicated that alterations in neurotrophic factors may be involved in the pathophysiology of TD, but the exact mechanisms need further investigation.

Cited by 6 publications

References 84 publications

BDNF, GDNF, NGF and Klotho levels and neurocognitive functions in acute term of schizophrenia

BDNF, GDNF, NGF and Klotho levels and neurocognitive functions in acute term of schizophrenia

Lower GDNF Serum Level Is a Possible Risk Factor for Constipation in Patients With Parkinson Disease: A Case–Control Study

Neurotrophic factors in bipolar disorders patients with manic episode

Contact Info

Product

Resources

About